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Top Ten Tips Palliative Care Clinicians Should
Know About Amyotrophic Lateral Sclerosis
Elyse A. Everett, MD, MOT,1 Elizabeth Pedowitz, MD,2 Samuel Maiser, MD,3 Joss Cohen, MD,4
Jessica Besbris, MD,4,5 Ambereen K. Mehta, MD, MPH,6
Luqi Chi, MD, MSCE,7 and Christopher A. Jones, MD, MBA8
Abstract
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative disorder with enormous
palliative care (PC) needs that begin at the time of diagnosis. Although it is an uncommon disease, clinicians who
work in PC or hospice are likely to encounter ALS somewhat frequently given the needs of patients with ALS with
regard to psychosocial support, symptom management, advance care planning (ACP), caregiver support, and end-
of-life care. As such, PC clinicians should be familiar with the basic principles of ALS symptoms, treatments,
disease course, and issues around ACP. This article, written by a team of neurologists and PC physicians, seeks to
provide PC clinicians with tips to improve their comfort and skills caring for patients with ALS and their families.
Keywords: ALS; amyotrophic lateral sclerosis; hospice; palliative care; symptom control
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressiveneurodegenerative disorder that causes severe weakness,
respiratory failure, and a host of other debilitating symptoms.
ALS is a devastating disease that is uniformly fatal, generally
within years of diagnosis.1 Palliative care (PC) needs in ALS
start essentially at the time of diagnosis (psychosocial support
and symptom management), evolve over the course of the ill-
ness (advance care planning [ACP] and caregiver support), and
intensify nearing the end of life (hospice care and bereavement
support).2 Patients with ALS are best cared for in multidisci-
plinary ALS clinics that typically include neurologists, pul-
monologists, nurses, physical and occupational therapists,
respiratory therapists, speech language pathologists (SLP),
social workers, and nutritionists.3
Society guidelines for the treatment of ALS advocate the
inclusion of PC in ALS care.4,5 Primary PC provided by neu-
rologists is ideal, given that almost all patients with ALS will be
under the care of a neurologist, but this can be severely limited
owing to neurologists’ limited PC training6 and clinical time
constraints. Specialist PC clinicians, on the contrary, may be
uncomfortable with the management of patients with ALS
because of the relative rarity of this disease and its unique
symptom management techniques, disease-directed treatment
options, and disease trajectory. Given that many patients with
ALS will end up being seen by PC or hospice at some point in
their disease course, it is important that all clinicians who care
for those with serious illness have an understanding of the
varied symptoms and management options, expected disease
progression, and distinctive end-of-life considerations in ALS.
In this article, 10 tips that physicians involved in the care of
patients with ALS consider important for PC clinicians to know
about this illness are provided.
Tip 1: There Are Two FDA-Approved
Disease-Modifying Medications for ALS
that Provide Modest Benefit over Placebo
Riluzole was approved in 1995 after a landmark trial
showed that it offered a two- to three-month survival benefit
over placebo; there are little data on how it affects the qual-
ity of life (QoL).7,8 Riluzole is a glutamate antagonist that
is taken orally twice daily. The main adverse effects include
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hepatotoxicity, fatigue, and gastrointestinal effects (nausea,
anorexia, and indigestion). The cost is *$1,000 per month.
Edaravone was approved in 2017 after a landmark trial
showed that it slowed the rate of functional neurologic de-
cline by *33% in a select subset of patients with low se-
verity of illness and had some positive effect on QoL.9
Edaravone is a free radical scavenger administered through
intravenous infusion (four-week cycle with two weeks on
and two weeks off) using a port or peripherally inserted
central catheter at home or in an infusion center. The adverse
effects include headache, constipation, gait disturbances, and
respiratory changes.9–11 There are data supporting its efficacy
up to 12 months, although the benefit is unclear past that point.
The cost is *$145,500 per year.
As with many medications for life-limiting illnesses, timing
of discontinuation is unclear. For riluzole, there is conflicting
evidence regarding the survival benefit in advanced stages of
the disease, and some studies suggest it may even be harmful
when used in advanced stages.12–14 There is no consensus, but
common considerations for discontinuation include advanced
stage (tracheostomy placement or hospice enrollment), medi-
cation side effects, and patient wish to avoid life-prolonging
treatments. Deciding when to stop edaravone is challenging
given the limited data on its long-term effect, but discontinuation
frequently happens naturally owing to patient preference, phy-
sician recommendation, insurance denials, or hospice election.
Tip 2: Clinicians Hesitate to Apply Existing
Prognostication Models to Individual Patients
Given the Heterogeneous Nature of ALS
Although ALS is uniformly fatal, extreme variability exists
within the disease course because of the notable phenotypic
variability of initial presentation, progression, and survival.
The general median survival time from symptom onset to
death ranges from 20 to 48 months, although 10% of patients
go on to survive longer than 10 years.1,15 Bulbar-onset ALS
has an even worse prognosis than the more common limb-
onset ALS, with a median survival of 2 years (greater than
10-year survival of only 3%).15
Several demographic and clinical factors correlate with
longer or shorter prognosis. Age is a strong predictor of
mortality; those with symptom onset before age 40 are more
likely to live longer (>10 years) than those with symptom
onset after age 80 (median survival 2 years).1 Those who
have concomitant frontotemporal dementia have a worse
prognosis. Most studies have found no difference between
sporadic and familial ALS in outcomes, although mutations
in SOD1 and genetic expansion of C9orf72 have been asso-
ciated with shorter survival.1,16
Diagnostic delay has been found to be a favorable indicator
as a shorter onset between symptom onset and diagnosis
likely indicates more aggressive disease. Although there are
diagnostic models that combine certain variables (weight
loss, forced vital capacity [FVC] change, functional capacity
decline, etc.) to predict time from symptom onset to either
death or respiratory insufficiency,16,17 physicians still hesi-
tate to give predictions to individual patients as survival times
can vary widely from months to over a decade. Overall, older
age, bulbar onset, and shorter diagnostic delay have the
strongest correlation with a poor prognosis.
Tip 3: There Is a Recognized Need for Early
and Regular Advance Care Planning Conversations
for Patients with ALS and Patients and Families
Generally Welcome These Discussions
ACP for patients with ALS is unique given the predictable
progression, lack of cure, and variety of symptoms that may
limit patient ability to participate meaningfully in complex
conversations at advanced disease stages. Cognitive impair-
ment is common in ALS and can influence decision-making
capacity. Pseudobulbar affect (PBA), dysarthria, and be-
havioral changes make communication difficult even if pa-
tients maintain decision-making capacity.18,19
ACP in ALS should start early, especially in cases of delayed
diagnosis and rapidly progressive disease, and should continue
throughout the disease course as treatment preferences often
change with symptom progression. Many clinicians worry that
patients and families may feel that discussions about ACP
happen too early, although framing ACP as a ‘‘normal part of
practice that is done with all patients’’ can eliminate that
concern. A ‘‘planning for the worst’’ approach has not been
shown to diminish hope or patient engagement. Studies have
instead shown that patients and families welcome the oppor-
tunity to discuss what to expect as the disease progresses.20
The most common components of ACP conversations in
ALS include code status, risks and benefits of life-sustaining
interventions (tracheostomy and gastrostomy tube [G-tube]),
and identifying a surrogate decision maker. It is important to
address intubation preference with the added education that
chronic respiratory failure may make safe extubation difficult
even in reversible illnesses like pneumonia, thereby forcing a
tracheostomy decision. Documentation of these decisions is
often done through advance directives (ADs) and, in some
states, Provider Orders for Life-Sustaining Treatment (POLST).
ALS-specific ADs are novel and currently being studied.20,21
ACP should also include an exploration of patient values
focused on what gives their life meaning and purpose. This
knowledge helps patients and physician choose the medical
interventions that have the best chance to offer meaningful
outcomes as defined by the patient.
Tip 4: Noninvasive Ventilation Can Improve Both
Quantity and Quality of Life for Patients with ALS,
but Oxygen Alone Should Never Be Used for Dyspnea
Respiratory failure in ALS develops because of respiratory
muscle weakness.22 Symptoms of respiratory insufficiency
include dyspnea, orthopnea, sleep disruption, morning head-
aches, and fatigue. Respiratory insufficiency typically begins
with nocturnal hypoventilation followed by daytime hypo-
ventilation as weakness progresses. Noninvasive ventilation
(NIV) is used to provide external respiratory support in those
with respiratory insufficiency.23 NIV has been shown to
prolong survival and improve QoL in patients with ALS who
can tolerate it,24 with earlier initiation providing more bene-
fit.25–27 Methods to improve patient comfort and compliance
with NIV include proper mask fittings, alternative mask types,
adjusting settings according to efficacy data and comfort, and
the concurrent use of dyspnea/anxiety medications.
NIV mode and settings should be carefully selected by a
physician familiar with neuromuscular disease and NIV.
Conventional NIV such as bilevel positive airway pressure
(BiPAP) can be used, but owing to rapid progression of















































weakness, BiPAP settings must be adjusted frequently to
maintain adequate respiratory support. This can be mitigated
by newer devices that offer volume-targeted pressure support
modes, including those that automatically adjust pressure
values to achieve targeted tidal volumes (average volume
assured pressure support or AVAPS). A significant barrier in
the past, some home ventilators now have batteries that allow
more freedom outside the home for when NIV is used during
awake time. Before entering hospice, patients may be re-
quired to transition from a home ventilator to a less expensive
BiPAP machine; assistance should be sought from someone
knowledgeable in NIV. Oxygen cannot be used to improve
dyspnea in patients with ALS and should never be used as a
replacement for NIV, as the problem in ALS-associated re-
spiratory failure is hypoventilation with hypercapnia rather
than hypoxia.
Tip 5: Not All Patients Benefit from Gastrostomy Tubes
Most patients with ALS develop dysphagia at some point in
their disease. This can lead to effortful mealtimes, weight loss,
malnutrition, and choking. Loss of appetite and inability to
feed oneself may also contribute to decreased oral intake.28 It is
important to have early consultation with an SLP at the first
sign of impaired chewing or swallowing. The SLP can rec-
ommend safe swallowing techniques and modifications of
food and liquid consistencies if needed. High-calorie and high-
protein nutritional supplements are often recommended.5 De-
pending on the severity of dysphagia and rate of weight loss,
the placement of a G-tube may be considered. It is impor-
tant for patients to understand that enteral feeding does not
have to replace oral feeding and can be used to supplement oral
intake.28
There are no randomized controlled trials (RCTs) com-
paring survival in those with and without G-tubes, and there
is no high-quality evidence on whether enteral nutrition af-
fects QoL in patients with ALS.5,28,29 The optimal timing of
G-tube placement is controversial with neurology academy
ALS guidelines recommending placement when FVC is
>50% of predicted to reduce peri-procedural risk.5,28 Risks of
G-tube placement include laryngeal spasm, infection, hem-
orrhage, failure to place, and death as a result of respiratory
arrest.
Given the paucity of data surrounding G-tube use in ALS
and difficulty in predicting the risks and benefits in individual
patients, emphasis should be placed on shared decision
making. Relevant concerns to discuss with patients include
how burdensome eating is, the weight loss curve, and their
preferences on surgical interventions and artificial nutrition.
Tip 6: Tracheostomy Is Often the Hardest Care
Decision in ALS
As the muscles of respiration weaken, patients are initially
managed on NIV. There may come a point when this will no
longer provide adequate ventilation and patients become in-
creasingly symptomatic. At this point, the patient must de-
cide between invasive ventilation with tracheostomy or
aggressive symptom management through hospice, often
causing patients to feel like they are choosing whether to live
or die. In western countries, a minority of patients with ALS
undergo tracheostomy (up to *15%).30
Patients who elect tracheostomy do so to prolong their life,
although median survival following tracheostomy can range
from eight months to three years with the majority dying
within one to two years.30,31 Survival is significantly shorter
for patients older than age 60.32 Patients with tracheostomies
can have an acceptable QoL with depression rates similar to
controls,31 but very little is known about the burden on
caregivers. Patients with ALS who have tracheostomies re-
quire 24-hour care at home or in long-term care facilities.
This level of care can create high physical, emotional, and
financial demands on families and caregivers.
In addition to describing the amount of care needed for
these patients, it is important to clearly define ‘‘endpoints’’
before tracheostomy placement. These endpoints are used to
identify the time when life prolongation is no longer ac-
ceptable to the patient and invasive ventilation should be
discontinued. For many, loss of ability to communicate is a
commonly chosen endpoint, so previous knowledge of their
wishes is necessary. The choice to undergo tracheostomy is
an incredibly complex decision, which should be a shared
decision among the patient, family, and physician.
Tip 7: There Are Multiple Causes of Pain/Discomfort
in ALS that Are Amenable to Different Treatments
Pain is a common but often underappreciated symptom of
ALS that can interfere with daily functioning and affect
QoL.33 There are multiple causes of pain and discomfort
including cramps, spasticity, neuropathic pain, joint pain, and
pressure sores. Clinicians must be familiar with identifying
the different types of pain and various treatment strategies
(Table 1). There is a lack of high-quality data for treatment of
pain in ALS.
Muscle cramps (sudden, involuntary muscle contractions)
are one of the most common causes of pain in ALS.34 Quinine
sulfate had traditionally been used but is no longer re-
commended because of safety concerns.4 A small RCT found
that mexiletine, a sodium channel-blocking antiarrhythmic,
reduces the frequency and severity of cramps.35 Although no
high-quality data exists, baclofen, magnesium, vitamin E,
gabapentin, and benzodiazepines are commonly used and
may be helpful. A daily stretching program can also help
alleviate these symptoms.
Spasticity (velocity-dependent increase in muscle tone) is
common in ALS, contributes to loss of voluntary movement,
and can be painful.36 Clinical practice guidelines recommend
physical therapy to maintain range of movement and prevent
contractures and consideration of oral therapy with baclofen
or tizanidine or intrathecal baclofen if spasticity is severe.5 It
is important to monitor for systemic side effects of oral an-
tispasticity medications as generalized weakness and seda-
tion can be debilitating. Low-dose botulinum toxin injections
may be helpful but require high-level expertise.37
Skin breakdown, pressure sores, and joint pain related to
immobility are other possible sources of pain and should be
monitored. There are special mattresses, pillows, and
custom-fitted wheelchairs to help prevent these, and frequent
repositioning and range of motion exercises are important.
Joint pain can be treated with acetaminophen and nonste-
roidal anti-inflammatory drugs. Pain may become severe
enough to warrant careful treatment with low-dose opiates
when refractory to other agents.















































Tip 8: Nonmotor Symptoms Like Fatigue, Excessive
Secretions, and Cognitive Changes are Common
in ALS and Can Be Treatable
Nonmotor symptoms of ALS commonly occur and can be
just as disabling as the motor symptoms. High-quality data
for the treatment of these symptoms is limited.
Fatigue is one of the most prevalent complaints and can be
difficult to treat, leading to impaired QoL.38 The etiology of
fatigue is multifactorial including muscle weakness, pain,
respiratory insufficiency, and decreased caloric intake.39
Early recognition and management of treatable comorbidities
are key to improving fatigue. Treatment can entail both
pharmacological therapy with modafinil, methylphenidate,
or amantadine and biopsychosocial modalities including
energy conservation, setting expectations, and relaxation
techniques.
Excess secretions are one of the most disabling nonmotor
symptoms of ALS and can lead to exacerbation of dysarthria
and respiratory failure, aspiration, and psychosocial distress.40
Anterior secretions (drooling) are differentiated from posterior
secretions (thick mucus leading to congestion) as treatment of
these two entities is distinct. Anterior secretions can be treated
with suctioning and anticholinergics such as amitriptyline,
atropine drops, glycopyrrolate, and scopolamine patches.
If refractory, botulinum toxin injections or irradiation to
the salivary glands can be considered.40 Posterior secre-
tions are more difficult to manage but can be treated with
hydration, guaifenesin, and cough assist machines.
PBA, reflexive outbursts of excessive or inappropriate
laughter or crying, affects 20–50% of patients with ALS, is
distressing to the patient and family, and can be easily mis-
diagnosed as depression. PBA can be managed with the
combination drug dextromethorphan and quinidine; selective
serotonin reuptake inhibitors (SSRIs) and tricyclic anti-
depressants (TCAs) can be trialed as well.4
ALS is associated with a range of psychological and
cognitive disturbances.41–43 Up to 50% of patients with ALS
have evidence of cognitive impairment and 15% meet criteria
for frontotemporal dementia. Frontotemporal dysfunction
includes issues with executive function, language, apathy,
loss of empathy, and disinhibition.
Tip 9: Patients and Families with ALS Carry a Host
of Psychosocial Needs Specific to This Illness
ALS confers a substantial psychosocial burden on patients
and families with studies indicating that psychosocial factors
may play a greater role in QoL than physical factors like
weakness.44 Patients with ALS often experience diagnostic
delays, enduring a year or more of potentially unnecessary
procedures or treatments, only to ultimately learn they have a
relentlessly progressive disease with limited treatments and
no cure, requiring immediate adjustment of their expectations
for their lives.
With an average age at diagnosis of 55 years, these patients
may be primary earners or parents of young children. Wor-
sening physical debility may require spouses and children to
step into new financial or caregiver roles that may lead to a
significant shift in relationship dynamics.45 The demands on
caregivers increase as the disease progresses. Because of
increasing physical and financial dependence, patients often
express worry about being a burden to family members; this
concern has been found to be particularly prevalent when
considering tracheostomy45 and may influence decision
Table 1. Pain Etiologies and Treatments






Antiepileptic drugs (levetiracetam or carbamazepine)
Vitamin E
Spasticity Baclofen (oral or intrathecal) Physical therapy
Tizanidine Stretching
Benzodiazepines Neutral-position splints for hands













Nonsteroidal anti-inflammatory drugs Massage
Opiates Warm and cold compresses
Antiepileptic drugs Acupuncture
Tetrahydrocannabinol and cannabidiol















































making regarding this intervention. The gradual loss of
physical ability and communication skills often leads to
social isolation, which may contribute to low mood or re-
duced QoL. Diagnosis with a life-threatening illness may
lead to spiritual distress, increasing the need for spiritual
support as well.
Despite these factors, low rates of depression have been
reported in ALS, although commonly used depression scales
may not be best suited to detect depression in this illness.46
When present, depression appears to be linked to shorter
survival times, controlling for age and disease severity.47
Higher perceived social support and confidence in the pa-
tient’s own coping potential may predict less depressed
mood, and studies have demonstrated the importance of so-
cial networks, family support, and technological aid de-
vices.46 Given the substantial influence of psychosocial
wellbeing on QoL, experts advocate a holistic approach in-
corporating psychosocial and spiritual support into clinical
care45 with acknowledgment that support needs may differ
between patients and their family members.
Tip 10: Although They Fear a Death from Suffocation,
Most Patients with ALS Die Peacefully in the Location
of Their Preference
The cause of death in most patients with ALS is respi-
ratory failure.22 The most common clinical scenario is an
acute deterioration in respiratory status followed by death
within a day or so.48,49 Consequently, a significant portion
of people with ALS fear that they are going to ‘‘choke’’ or
‘‘suffocate’’ to death, which can provoke anxiety and de-
pression and a wish and/or request to die.50 Fortunately, the
majority of patients with ALS die peacefully48 and in the
location of their choosing,51 be it at home or in an inpa-
tient hospice unit. The most common symptoms experi-
enced by patients with ALS at the end of life are dyspnea,
anxiety, pain/discomfort, and insomnia,48,51 which if as-
sessed for can be adequately controlled with opiates, ben-
zodiazepines, and other medications. Many patients choose
to discontinue use of NIV or invasive ventilation at the end
of life,51 especially if they feel it is keeping them alive in an
unwanted state or prolonging their death. Patients with ALS
should be informed during routine visits that while their
likely cause of death will be respiratory related, it is very
uncommon for people to choke or suffocate to death and
their death will most likely be peaceful. Their concerns
about end-of-life should be queried and they should be
reassured that their terminal symptoms can nearly always
be controlled.
Conclusion
ALS is a rapidly progressive and widely symptomatic
neurodegenerative condition that is always fatal and causes
significant amounts of suffering to patients and their care-
givers. PC clinicians should be familiar with the expected
disease course, symptoms and treatments, common ACP
decisions, and end-of-life care for ALS to provide the best
possible care to those with this devastating disease.
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